Should I buy BrightSpring Health Services (BTSG) stock or is it too late?

BrightSpring Health Services · Health Care · price $61

See the full BrightSpring Health Services (BTSG) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Guggenheim — 77% of its targets hit on this sector (52 calls tested). It aims for $81 (+33 %), call made on July 14, 2026, maturing on July 14, 2027 (45 d ago).

The 7 reliable analysts $81+33 %

The 6 other firms $72+18 %

How to read it: the 7 reliable firms are not filtered by optimism — 7 aim above the price, 0 below, hence their $81 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.

In short — Should you invest in BrightSpring Health Services? Is it too late, still worth it? Analysts are overwhelmingly positive (100% buy, median target $80, i.e. +31%), and the most reliable on BTSG targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

100% of analysts rate it a buy (Buy consensus, 13 ratings) — a sign of market conviction.
Median price target $80, i.e. +31% from the current price ($61).
The most reliable firm on BTSG, Morgan Stanley (100% hit rate, 3 scored calls), targets $80 (call made on July 14, 2026, maturing on July 14, 2027) (+31%) in its most recent call, and $32 (call made on October 14, 2025, maturing on October 14, 2026) (-47%) in the one coming due soonest.

⚠️ Reasons to hesitate

A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.
A near-unanimous consensus leaves little room for positive surprise — a lot of optimism is already baked in.

The analyst consensus on BTSG

Median target $80 (+31%) · 13 ratings · Buy consensus

Strong Buy00%

Buy13100%

Hold00%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in BrightSpring Health Services now?

We won't decide for you. The facts: 100% of analysts rate it a buy, median target $80 (+31%), and Morgan Stanley (most reliable on BTSG, 100%) targets $80. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in BrightSpring Health Services?

Not according to analysts: the median target ($80) is still +31% above the current price ($61) (most reliable on BTSG: Morgan Stanley, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is BrightSpring Health Services still worth investing in?

It depends on the gap between the price ($61) and its estimated value: analysts target $80 on median (+31%), with 100% buys (most reliable on BTSG: Morgan Stanley, 100%). Cross-check with their real reliability on BTSG and the cautions above. Information, not advice.

What's the main risk in buying BTSG?

A 12-month target is not a guaranteed path: the price can fall in the meantime.

→ Go deeper: the full BrightSpring Health Services profile (consensus, analyst reliability, price target, performance).